Skip to content

Daily Egg Consumption and Cognitive Function in Older Adults

Daily Egg Consumption and Cognitive Function in Older Adults

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05460624
Enrollment
0
Registered
2022-07-15
Start date
2023-02-10
Completion date
2023-02-10
Last updated
2023-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognition

Brief summary

The purpose of this study is to test the effects of provisioning twelve eggs weekly, incorporated into breakfast meals, on composite scores of executive functioning and memory using the CNSVS computerized test platform in older adults in a randomized study.

Detailed description

Procedure: This study will test the effects of incorporating eggs at breakfast versus breakfasts that match a typical American breakfast on executive function and composite memory in adults 65 to 90 years old. Randomization: Participants will be randomized using a permuted block randomization scheme to balance randomization across time with rolling enrollment, while ensuring allocation concealment through block sizes unknown to the investigators. Randomization will be also stratified by whether the individual participant is being randomized or multiple people from the same household (e.g., a couple being randomized together). This is to balance the number of randomized individual participants and households across the two conditions. Participants will be assigned sequentially Analysis plan: An intention-to-treat analysis approach will be followed for data analysis. Primary statistical approach will be linear mixed models, including time, group, and their interaction as factors, where the interaction is the main test of interest to determine if the treatment group improved significantly more than the control group. The model will also include random effects for subjects (to account for repeated measurements) and for households (to adjust for clustering effect). Covariates for pre-randomization variables such as age, sex, education level, and computer familiarity may be included to account for variation in the outcomes and thereby improve power for the test of the intervention. For joint primary outcomes, we will split alpha of 0.05 between the two outcomes (p\<0.025 for two-sided statistical significance). We will perform a compliers (threshold to be specified) and completers (those with both pre- and post-values) analysis as pre-specific secondary analyses on the primary outcomes. For pre-specified secondary outcomes, we will use the primary approach for the list of secondary outcomes. Results will be presented with and without multiple comparison or false discovery rate (FDR) corrections, and all analyzed outcomes will be reported.

Interventions

OTHEREgg-containing breakfast

Involves participants eating six premade egg-containing breakfast meals per week for 12 weeks. Each meal contains 2 eggs to provide 12 eggs per week.

OTHERTypical American-style breakfast excluding eggs

Involves participants eating six premade egg-excluding breakfast meals per week for 12 weeks. Breakfast meals are matched to the intervention egg-containing breakfast meals on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.

Sponsors

American Egg Board
CollaboratorOTHER
Indiana University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Masking description

Outcome assessments will be conducted before randomization at baseline and by individuals blinded to the treatment assignments at follow-up. Data will be analyzed prior to unblinding.

Eligibility

Sex/Gender
ALL
Age
65 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Participant has autonomy over their food choices. * Participant has the common appliances for storing refrigerated and frozen foods (i.e., refrigerator and freezer). * Participant has common appliances to defrost/prepare foods (e.g., microwave oven, oven, stove, etc.). * Participant has sufficient corrected visual acuity to read simple instructions on a computer/laptop screen * Participant has a CNSVS standard (age-matched) score of 85-105 (inclusive) for either the domain composite memory (raw score is the sum of verbal memory score and visual memory score) or the domain executive function, and 80-110 for the other. * Participant has no plans to change their routine (physical activity pattern, dietary habits, sleep pattern, smoking habits) during the study period unless advised as part of study participation. * Participant is willing to follow screening/assessment visit instructions. * Participant is willing to consume the study foods as provided at the breakfast meals during the study period. * Participant is willing and able to visit IUB campus on specified in-person visit days. * Participant understands the study procedures and signs the informed consent to participate in the study and is willing to complete study procedures.

Exclusion criteria

* Participant is not fully vaccinated for COVID-19. * Participant reports habitually consuming greater than 5.5 eggs per week. * Participant has sensitivity, allergy, taste aversion, or other aversion (e.g., vegan) to any ingredient of the study food. * Participant has substantial dietary restrictions (e.g., chronic kidney disease or familial hypercholesterolemia diet) that, based on the judgment of the Principal Investigator, would interfere with the intervention. * Participant has an established diagnosis of or is under treatment for dementia or ADHD. Anxiety or depression are not exclusionary. * Participant is under active chemotherapy treatment. * Participant is participating in a parallel research study that, based on the judgment of the Principal Investigator, would interfere with his or her ability to comply with the study protocol, or which might confound the interpretation of the study results. * Participant is not able to read. * Participant reports current use of cognitive enhancing medications, attention/concentration enhancing medications, anticonvulsant medications, and mood stabilizing medications. * Participant has a condition that, based on the judgment of the Principal Investigator, would interfere with his or her ability to provide informed consent or comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk.

Design outcomes

Primary

MeasureTime frameDescription
Composite Memory12-weekDerived from the CNSVS verbal and visual memory test scores
Executive Function12-weekDerived from Shifting Attention Test (SAT) from CNSVS battery of tests

Secondary

MeasureTime frameDescription
Processing speed12-weekDerived from symbol digit coding test of CNSVS battery of tests
Reaction time12-weekDerived from Stroop test of CNSVS battery of tests
Verbal memory12-weekDerived from verbal memory test of CNSVS battery of tests
Working memory12-weekDerived from 4-Part continuous performance of CNSVS battery of tests
Sustained Attention12-weekDerived from 4-Part continuous performance of CNSVS battery of tests
Simple Attention12-weekDerived from continuous performance of CNSVS battery of tests
Visual memory12-weekDerived from visual memory test of CNSVS battery of tests

Other

MeasureTime frameDescription
Dietary intakes12-weekMeasurement tool: 3-day food record
Body composition12-weekMeasurement tool: Dual-energy X-ray absorptiometry (DEXA)
Physical performance12-weekMeasurement tool: The Short Physical Performance Battery (SPPB)
Serum total cholesterol12-week
Serum LDL cholesterol12-week
Serum HDL cholesterol12-week
Serum total triglycerides12-week
Blood Pressure12-week
Heart rate12-week
Skin carotenoids score12-weekMeasurement tool: The Vegie Meter®

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026